Novo Nordisk's Ozempic is the preferred GLP-1 analogue in Denmark

The Danish Health Authority has appointed Novo Nordisk's new drug Ozempic as first choice of GLP-1 analogues for treating type 2 diabetes. However, it does not apply to patients with cardiovascular problems or the eye disease diabetic retinopathy.

Photo: /ritzau/AP/Novo Nordisk

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles